BioStrand

MindWalk (operating at biostrand.ai) is an all-in-one biointelligence ecosystem purpose-built for biologics discovery and development. The platform integrates AI, deep biological data, and advanced laboratory research into a unified, customizable environment that makes complex biology more computable and actionable — spanning therapeutic antibodies, anti-drug antibodies, diagnostics, vaccines, nanobodies, and peptide therapeutics. Because no two programs are identical, the ecosystem is designed to adapt to different targets, modalities, and program priorities, supporting greater precision, deeper context, and faster iteration from target identification through to the clinic.

MindWalk serves biopharmaceutical and biotechnology organizations at every stage of discovery and development. With more than 15 molecules advanced to the clinic through partner collaborations, and validated partnerships with companies such as Acumen Pharmaceuticals, GentiBio, OncoResponse, and Amyl Therapeutics, MindWalk combines the expertise of technologists and scientists working side by side to deliver integrated discovery solutions.

Core Platform Components

• LensAI™ (Bio-Native AI): MindWalk's proprietary AI engine is built to interpret biology from the ground up rather than simply trained on data. LensAI connects molecular, structural, functional, and literature-derived data to generate deeper biological insight and support clearer understanding across complex biological systems. It is described as bio-native intelligence built on biological meaning.
• HYFT® Technology (Deep Data Integration): The HYFT framework links more than 25 billion biological relationships within LensAI, organizing previously siloed data into connected, discovery-ready insight. HYFT technology has been applied to detect functional adjacency linked to portfolio risk in AI-designed therapeutics and underpins the platform's ability to identify conserved epitopes and other high-value molecular patterns at scale.
• Advanced Lab Research: MindWalk's laboratory capabilities work in close conjunction with its computational platform. Experimental work is informed by LensAI analysis, supporting stronger program starts, deeper biological context, and more informed progression toward the clinic. The lab has contributed to the advancement of over 15 molecules into clinical development.

Key Products and Discovery Platforms

• B Cell Llama™: A nanobody discovery platform specifically designed for the bispecific antibody and cell therapy era, reflecting MindWalk's expansion into next-generation therapeutic modalities.
• B Cell Select: An antibody discovery platform that has been central to developing lead immunoinhibitory receptor drug candidates, including programs that have progressed to Phase I/II clinical trials.
• Rapid Prime Immunization Method: A proprietary immunization approach that has proven pivotal in enabling timely identification of human immunotherapeutics, including sabirnetug, currently in Phase 2 clinical trials for Acumen Pharmaceuticals.

Core Capabilities and Scientific Applications

• Epitope Mapping: LensAI has demonstrated computational insights reaching crystallographic-level accuracy for epitope mapping, with precision aligned with x-ray crystallography results, strengthening experimental confidence through predictive context.
• Vaccine Design: Using LensAI's pattern detection capabilities, MindWalk identified a highly conserved epitope shared across all four dengue virus serotypes, opening new directions in vaccine design and demonstrating the platform's ability to expand what can be discovered at scale.
• Neurodegenerative Disease: MindWalk has validated platform precision through a breakthrough discovery targeting pathogenic TDP-43 in neurodegenerative disease, and has supported optimization of Pan-Amyloid Immunotherapy candidates through in silico screening, developability analysis, and protein engineering.
• Autoimmunity and Inflammation: The platform has been applied to generate specific binders against targets in autoimmunity and inflammation, with customized discovery approaches combining laboratory and LensAI capabilities.
• Developability Analysis and Protein Engineering: LensAI supports in silico screening and protein engineering workflows to accelerate candidate discovery and strengthen candidate performance.

Validated Outcomes and Partner Testimonials

• Acumen Pharmaceuticals credited MindWalk's Rapid Prime immunization method and antibody discovery technology as pivotal to identifying sabirnetug, now in Phase 2 clinical trials.
• GentiBio highlighted MindWalk's proven expertise and customized discovery approach, noting that results from both the laboratory and LensAI platform exceeded expectations for autoimmunity and inflammation targets.
• OncoResponse identified the B Cell Select platform as central to developing lead immunoinhibitory receptor drug candidates now in Phase I/II clinical trials.
• Amyl Therapeutics noted that LensAI, powered by HYFT technology, accelerated their discovery process and strengthened candidate performance for Pan-Amyloid Immunotherapy in neurodegenerative disease.

Resources and Knowledge Sharing

• CaseXCase Series: A dedicated case study collection showcasing LensAI in action across discovery workflows, applying explainable intelligence to demonstrate contextual analysis and measurable outcomes.
• Scientific Posters: Published materials illustrating how MindWalk powers smarter, faster paths from concept to clinic.
• Blogs and Technical Content: Ongoing publication of ideas and insights reshaping the future of biologics discovery.

MindWalk's integrated biointelligence ecosystem represents a convergence of AI, biological data infrastructure, and hands-on laboratory science — offering life sciences organizations a unified platform to navigate the full complexity of modern biologics discovery and accelerate programs from early target identification through clinical advancement.